Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab in Resectable Non-functioning Pituitary Adenoma
NCT01203618Phase 2Withdrawn
- Sponsor
- Morphotek
- Start
- Feb 2011
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of farletuzumab in non-functioning pituitary adenoma (NFPA), sponsored by Morphotek. Primary endpoint: Efficacy of farletuzumab as measured by objective response in the tumor size. Planned start Feb 2011; status: withdrawn.
02
Drugs
farletuzumab
03
Conditions
non-functioning pituitary adenoma (NFPA)
Beyond the preview
Go deeper on NCT01203618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203618.